Morgan Stanley Comments on Performance at Boston Scientific

Morgan Stanley has published a report on Boston Scientifics (NYSE: BSX) outlining general operating numbers for the medical device developer.

In the report, Morgan Stanley wrote, "Revenue and margin uncertainty keep us from a more constructive outlook despite progress on cost initiatives and the new repurchase program. Boston is taking appropriate steps to improve results amid difficult end markets, but we're not yet convinced it's a recipe for outperformance."

Morgan Stanley rated Boston Scientific an Equal-weight with no price target given. Boston Scientific closed Thursday at $7.28.